The evolution of health research co-production with Indigenous peoples.
XOMA to buy Kinnate; A pain biotech’s small IPO
Plus, news about Blueprint Medicines, Sosei Group and Poxel: XOMA to buy Kinnate Biopharma: The biotech royalty aggregator said it would pay $2.33 per share